Novel Therapies for Stargardt Disease

Both gene-targeted and gene-agnostic treatments have been shown to restore ABCA4 function and impact broader retinal processes.

By: Cesar Estrada-Puente, MD, Paula C. Morales, MD, Ramiro S. Maldonado, MD

Retinal Physician October 1, 2025 Vol 22, Issue October 2025 Page(s): 19-22

Clinical Report: Novel Therapies for Stargardt Disease

Overview

Recent advancements in therapies for Stargardt disease (STGD) show promise in slowing disease progression and preserving vision. Notably, ALK-001 and tinlarebant have demonstrated significant effects in clinical trials, highlighting the potential for disease-modifying treatments.

Background

Stargardt disease is the most common inherited macular dystrophy, affecting approximately 1 in 10,000 individuals. It is caused by mutations in the ABCA4 gene, leading to toxic accumulation of bisretinoids in the retinal pigment epithelium and subsequent photoreceptor degeneration. The lack of approved therapies underscores the urgent need for effective treatment options.

Data Highlights

Study	Participants	Outcome
TEASE-1	50	21.6% reduction in atrophic lesion progression (P<.001)
TEASE-2	80	Ongoing, results expected in 2025
TEASE-3	7	Preserved retinal structure and function
Tinlarebant Phase 1b/2	Adolescents	Trend toward slowing QDAF expansion
Tinlarebant Phase 2	12	50% reduction in DDAF lesion growth (P<.001)

Key Findings

ALK-001 significantly slowed atrophic lesion progression by 21.6% over 24 months in the TEASE-1 trial.
Tinlarebant demonstrated a favorable safety profile and potential to stabilize visual acuity in adolescents.
TEASE-3 trial results indicated preserved retinal structure in treated adolescents compared to untreated siblings.
Ongoing trials (TEASE-2 and TEASE-4) aim to further evaluate the long-term safety and efficacy of ALK-001.
Tinlarebant's Phase 2 data showed a 50% reduction in lesion growth compared to historical controls.

Clinical Implications

The findings from recent trials suggest that ALK-001 and tinlarebant may offer new avenues for managing Stargardt disease, potentially altering the disease course. Clinicians should consider enrolling eligible patients in ongoing clinical trials to access these promising therapies.

Conclusion

The development of novel therapies for Stargardt disease represents a significant advancement in the management of this condition. Continued research and clinical trials are essential to validate these findings and establish effective treatment protocols.

PentaVision

Retinal Physician